Enterprise Life Sciences Data Analytics Platforms sector
Strategic acquirers, private equity (buyout funds and growth funds) firms, and valuation benchmarks for Enterprise Life Sciences Data Analytics Platforms
1.1 - About Enterprise Life Sciences Data Analytics Platforms sector
Companies in this category provide cloud-based data and analytics platforms that consolidate research content, real‑world evidence, and R&D workflows for life sciences. They deliver curated datasets, interoperable pipelines, and decision-support tools spanning discovery through commercialization. Enterprise Life Sciences Data Analytics Platforms help customers identify targets, plan trials, validate treatment pathways, and generate market and regulatory insights with traceable, de‑identified data and configurable software.
Typical offerings include longitudinal real‑world data lakes linked to provider and patient graphs, AI‑driven target discovery and de novo protein design, and ELN/LIMS suites with workflow templates for cell and gene therapy. Strategic buyers in this space deliver clinical trial feasibility, site universe analytics, and investigator identification; research intelligence with citation indexing and literature access; biomarker assay networks and human biospecimen sourcing; pharmacometrics and PK/PD modeling; and evidence validation tools that align care plans with guidelines.
Primary customers include biopharma R&D organizations, biotechnology startups, and contract research firms, with adoption also spanning academic medical centers. These platforms reduce discovery timelines, improve trial design and site selection, raise data quality and governance, and cut research procurement costs. They enable faster evidence generation for regulatory submissions, optimize launch planning through market insights, and enhance payer‑provider transparency where clinical validation is required.
2. Buyers in the Enterprise Life Sciences Data Analytics Platforms sector
2.1 Top strategic acquirers of Enterprise Life Sciences Data Analytics Platforms companies
Clarivate
HQ: United States
Website
- Description: Provider of subscription-based analytics and intelligence solutions that deliver bibliometric and scientometric insights, business and market intelligence, intellectual property and trademark protection, regulatory compliance data and brand/domain protection. Clarivate calculates journal impact factors via Web of Science and markets product families such as EndNote, Cortellis, Derwent, CompuMark and ProQuest.
- Key Products:
- Web of Science: Paid-access platform offering multidisciplinary citation and reference databases from journals, conference proceedings and books, enabling researchers to track impact and discover relevant literature
- Cortellis: Suite of life-science intelligence tools providing regulatory, competitive, clinical trial, deals and drug discovery data to guide decisions across drug and device development
- Derwent Solutions: Patent databases such as Derwent World Patents Index and tools like Derwent Innovation and Data Analyzer that deliver searchable, analyzed patent sequences and case law for IP lifecycle management
- CompuMark: Trademark research services including SAEGIS online screening
- TM go365 self-service search, analyst-driven Full Search and Watching services to evaluate and monitor marks for infringement worldwide.
- Rationale: Provider of Web of Science citation index, Cortellis life-science intelligence, and Derwent Innovation patent analytics for R&D decisions.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Enterprise Life Sciences Data Analytics Platforms sector
M&A buyer group 1: Life Sciences Analytics
19 companies
View group →
Description: Companies in this category build analytics software tailored to biopharma and medtech, integrating R&D, clinical, safety, and commercial data to generate actionable insights across the product lifecycle. Enterprise Life Sciences Analytics Platforms help users unify disparate datasets, model outcomes, and operationalize evidence, enabling faster decisions in discovery, trial design, pharmacovigilance, and market access while improving data quality, regulatory readiness, and collaboration across global teams.
Clarivate
- Type: N/A
- Employees: ●●●●●
- Description: Provider of subscription-based analytics and intelligence solutions that deliver bibliometric and scientometric insights, business and market intelligence, intellectual property and trademark protection, regulatory compliance data and brand/domain protection. Clarivate calculates journal impact factors via Web of Science and markets product families such as EndNote, Cortellis, Derwent, CompuMark and ProQuest.
- Key Products:
- Web of Science: Paid-access platform offering multidisciplinary citation and reference databases from journals, conference proceedings and books, enabling researchers to track impact and discover relevant literature
- Cortellis: Suite of life-science intelligence tools providing regulatory, competitive, clinical trial, deals and drug discovery data to guide decisions across drug and device development
- Derwent Solutions: Patent databases such as Derwent World Patents Index and tools like Derwent Innovation and Data Analyzer that deliver searchable, analyzed patent sequences and case law for IP lifecycle management
- CompuMark: Trademark research services including SAEGIS online screening
- TM go365 self-service search, analyst-driven Full Search and Watching services to evaluate and monitor marks for infringement worldwide.
🔒
🔒
🔒
View all 19 companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms in Enterprise Life Sciences Data Analytics Platforms sector
3.1 - Buyout funds in the Enterprise Life Sciences Data Analytics Platforms sector
2.2 - Strategic buyer groups for Enterprise Life Sciences Data Analytics Platforms sector
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Enterprise Life Sciences Data Analytics Platforms companies
4.2 - Public trading comparable groups for Enterprise Life Sciences Data Analytics Platforms sector
Valuation benchmark group 1: Biologic Drug Discovery Tools Companies
3 companies
View group →
Description: Companies in this trading comparable group are public providers of biologics-focused discovery tools and platforms. They supply recombinant proteins, antibodies, assay reagents, and custom production plus AI-enabled design services that accelerate preclinical research and therapeutic development. They are grouped as comparables given shared catalog and services revenue models, overlapping pharma and research customers, and biotech tools margin profiles, offering consistent public trading comparables for valuation.
Vazyme Biotech
- Enterprise value: $●●●m
- Market Cap: $●●●m
- EV/Revenue: ●.●x
- EV/EBITDA: ●●.●x
- Description: Provider of biotechnology solutions specializing in the design, manufacture, and application of bioactive proteins and compounds. The company focuses on innovative enzyme-based solutions for clinical and molecular diagnostics, among other applications.
- Key Products:
- COVID-19 Solution: Comprehensive assay and diagnostic solutions for COVID-19 testing, including qPCR kits and antibodies
- Molecular Biology Solutions: Offering reagents for PCR, qPCR, and NGS applications, catering to research and diagnostic needs
- Custom Oligos: Providing custom oligonucleotide synthesis services with a focus on high-performance and precision
- Enzyme Technologies: Development and manufacturing of enzyme solutions for diverse biological applications
- Reagent Kits: Producing high-quality reagent kits for DNA and RNA extraction and sequencing.
🔒
🔒
🔒
View all 3 companies in this group
Request Free Trial Now →
🔒
Revenue growth
Median
15.7%
2025E
16.0%
2026E
EBITDA margin
Median
28.2%
2025E
28.6%
2026E
Cash EBITDA margin
Median
27.6%
2025E
28.0%
2026E
EV/Revenue
Median
8.4x
2025E
6.8x
2026E
EV/EBITDA
Median
28.9x
2025E
24.4x
2026E
EV/Cash EBITDA
Median
29.0x
2025E
25.5x
2026E
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →